Ultra Nasdaq Biotechnology - BIB Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the NASDAQ Biotechnology Index®.

Index/Benchmark Summary

The NASDAQ Biotechnology Index is a modified capitalization weighted index that includes securities of The NASDAQ Stock Market listed companies that are classified as either biotechnology or pharmaceutical. The securities also meet other eligibility criteria determined by The NASDAQ OMX Group, Inc., including minimum market capitalization and liquidity requirements.

Fundamentals as of 9/30/14

Total Number of Companies 118
Price/Earnings Ratio 37.18
Price/Book Ratio 7.60
Dividend Yield *(%) 0.18
Average Index Market Capitalization $6.65 billion

* Derivative contracts are priced to reflect the underlying index yield and will not generate dividend income. Because ProShares invest in derivatives, they will not have dividend distributions that reflect those of their applicable indexes.

Index Holdings Information as of 9/30/14

Top 10 Index Companies Weight
Amgen Inc. 8.29%
Celgene Corp. 8.21%
Gilead Sciences Inc. 8.14%
Biogen Idec Inc. 7.94%
Regeneron Pharmaceuticals Inc. 7.36%
Vertex Pharmaceuticals Inc. 4.94%
Alexion Pharmaceuticals Inc. 4.03%
Mylan Inc. 3.83%
Illumina Inc. 3.76%
BioMarin Pharmaceutical Inc. 2.39%

ProShares may invest in financial instruments (including derivatives) that, in combination, should have similar daily price return characteristics to the fund's benchmark.

Index Sector Weightings § Weight
Biotechnology 73.20%
Pharmaceuticals 23.87%
Health Care Products 2.56%
Holding Companies-Divers 0.21%
Commercial Services 0.16%

§ Sum of weightings may not equal 100% due to rounding.